→ BeyondSpring, a biotech with deep roots in China, has completed an unusual IPO this week. After initially targeting an offering designed to raise $100 million, the biotech ended up selling 174,286 shares at $20 and then executed a private offering to insiders for another 2.5 million shares. The total amounted to $54 million. The company has a cancer drug in several studies.
→ The FDA has extended Radius Health’s PDUFA date on Abaloparatide-SC by three months. The new deadline is June 30.
→ Pharnext has agreed to combine its platform tech with Galapagos’ preclinical drug candidates to create new drug combos. “Pharnext has already obtained promising clinical results with its cutting-edge technology, which has encouraged us to collaborate,” said Galapagos CEO Onno van de Stolpe. “We are very pleased to collaborate with Pharnext and to benefit from Pharnext’s expertise in deciphering diseases’ molecular networks. We hope that this will reinforce Galapagos’ R&D capabilities to generate new therapeutic approaches in a highly efficient and modern manner.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 24,000+ biopharma pros who read Endpoints News by email every day.Free Subscription